CORTRIUM 40 mg/2 ml polvere e solvente per soluzione iniettabile clinical trials

Obinutuzumab for primary membranous nephropathy: a pilot study in patients with rituximab-resistant or rituximab-dependent nephrotic syndrome and in patients intolerant to rituximab (the ORION study)

This study looks at a new drug, Obinutuzumab, for a kidney disease called primary membranous nephropathy. It's for people whose disease hasn’t responded well to a common treatment called rituximab, or if they can’t take rituximab. We want to see how well it works and if it's safe.